Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A prospective, multicenter, randomized in a 2:1 ratio, controlled, clinical trial with two
parallel arms will be conducted to compare irinotecan dose escalated FOLFIRI according to
UGT1A1 genotyping plus 120 mg regorafenib with 120 mg regorafenib alone in previously treated
patients with metastatic colorectal cancer (mCRC).
Phase:
Phase 2
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital